Sun Hwayeon, Shin Jinyoung, Kim Min-Ji, Bae Sunghwan, Lee Nicole Dain, Yoo Byungwook
Department of Family Medicine, Soonchunhyang University Seoul Hospital, Seoul 04401, Republic of Korea.
Department of Family Medicine, Konkuk University Medical Center, Seoul 05030, Republic of Korea.
J Clin Med. 2024 Apr 26;13(9):2559. doi: 10.3390/jcm13092559.
: WCFA19 ( WIKIM51), found during the fermentation of kimchi, is known for its inhibitory effects on body weight and body fat. This study looked at the impact of WCFA19 isolated from dandelion kimchi on weight loss in overweight and obese adults that are otherwise healthy. : This study was conducted as a multicenter, double-blind, randomized, placebo-controlled study with 104 overweight and obese subjects. Subjects were randomized evenly into the test group (WCFA19, 500 mg, = 40) or control group ( = 34) for 12 weeks from 14 June 2021 to 24 December 2021. Effects were based on DEXA to measure changes in body fat mass and percentage. : Among the 74 subjects analyzed, WCFA19 oral supplementation for 12 weeks resulted in a significant decrease in body fat mass of 633.38 ± 1396.17 g ( = 0.0066) in overweight and obese individuals in the experimental group. The control group showed an increase of 59.10 ± 1120.57 g ( = 0.7604), indicating a statistically significant difference between the two groups. There was also a statistically significant difference ( = 0.0448) in the change in body fat percentage, with a decrease of 0.41 ± 1.22% ( = 0.0424) in the experimental group and an increase of 0.17 ± 1.21% ( = 0.4078) in the control group. No significant adverse events were reported. : Oral supplementation of 500 mg of WCFA19 for 12 weeks is associated with a decrease in body weight, particularly in body fat mass and percentage.
WCFA19(WIKIM51)是在泡菜发酵过程中发现的,以其对体重和体脂的抑制作用而闻名。本研究观察了从蒲公英泡菜中分离出的WCFA19对其他方面健康的超重和肥胖成年人减肥的影响。本研究作为一项多中心、双盲、随机、安慰剂对照研究,共有104名超重和肥胖受试者参与。从2021年6月14日至2021年12月24日,受试者被平均随机分为试验组(WCFA19,500毫克,n = 40)或对照组(n = 34),为期12周。效果基于双能X线吸收法(DEXA)来测量体脂质量和百分比的变化。在分析的74名受试者中,试验组超重和肥胖个体口服WCFA19 12周后,体脂质量显著减少633.38±1396.17克(P = 0.0066)。对照组增加了59.10±1120.57克(P = 0.7604),表明两组之间存在统计学显著差异。体脂百分比的变化也存在统计学显著差异(P = 0.0448),试验组下降了0.41±1.22%(P = 0.0424),对照组增加了0.17±1.21%(P = 0.4078)。未报告重大不良事件。口服500毫克WCFA19 12周与体重下降有关,尤其是体脂质量和百分比。